Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina
ConclusionsWe found an incidence density of breakthrough COVID-19 infection of 3.5 × 10.000 patients/day (95% CI 2.3–6.7) after vaccination in Argentina. (Source: Neurological Sciences)
Source: Neurological Sciences - December 30, 2023 Category: Neurology Source Type: research
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial
Volume 23, Issue 12, July - December 2023, Page 1287-1297 . (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - December 28, 2023 Category: Drugs & Pharmacology Authors: Hendrik WesselsOliver von RichterMaria VelinovaJosef H öflerPaul ChamberlainArno KrommingaDirk LehnickKarsten Rotha Polpharma Biologics S.A, Gdansk, Polandb Hexal AG (A Sandoz company), Holzkirchen, Germanyc Early Development Services, ICON, Groningen, T Source Type: research
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry
ConclusionsMore than 50% of RMS switched therapy due to disease activity. HE DMTs, especially anti-CD20 drugs, significantly reduce the risk of treatment switch. (Source: Journal of Neurology)
Source: Journal of Neurology - December 22, 2023 Category: Neurology Source Type: research
Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials
AbstractThe present study aims to describe the state of the art of fluid biomarkers use in ongoing multiple sclerosis (MS) clinical trials.A review of 608 ongoing protocols in the clinicaltrials.gov and EudraCT databases was performed. The trials enrolled patients with a diagnosis of relapsing remitting MS, secondary progressive MS, and/or primary progressive MS according to Revised McDonald criteria or relapsing MS according to Lublin et al. (2014). The presence of fluid biomarkers among the primary and/or secondary study outcomes was assessed.Overall, 5% of ongoing interventional studies on MS adopted fluid biomarkers. T...
Source: Neurological Sciences - December 20, 2023 Category: Neurology Source Type: research
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research
Varicella-zoster virus vasculopathy in a patient with multiple sclerosis receiving natalizumab
We present a case of a woman in her 30s with relapsing-remitting multiple sclerosis, treated with natalizumab, who developed ophthalmic varicella zoster virus (VZV) infection, with subsequent vasculopathy causing cerebral ischaemic lesions. She was treated with acyclovir, prednisolone and acetylsalicylic acid and fully recovered. VZV vasculopathy is associated with stroke and immunomodulating treatments may increase the risks of these adverse events. To date, nine VZV-related vasculopathy cases in patients treated with natalizumab have been reported in English literature and are summarised in this paper. Although rare, VZV...
Source: Herpes - December 11, 2023 Category: Infectious Diseases Authors: Anna Elmst åhl Fredrik Buchwald Andreea Ilinca Source Type: research
Varicella-zoster virus vasculopathy in a patient with multiple sclerosis receiving natalizumab
We present a case of a woman in her 30s with relapsing-remitting multiple sclerosis, treated with natalizumab, who developed ophthalmic varicella zoster virus (VZV) infection, with subsequent vasculopathy causing cerebral ischaemic lesions. She was treated with acyclovir, prednisolone and acetylsalicylic acid and fully recovered. VZV vasculopathy is associated with stroke and immunomodulating treatments may increase the risks of these adverse events. To date, nine VZV-related vasculopathy cases in patients treated with natalizumab have been reported in English literature and are summarised in this paper. Although rare, VZV...
Source: Herpes - December 11, 2023 Category: Infectious Diseases Authors: Anna Elmst åhl Fredrik Buchwald Andreea Ilinca Source Type: research
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - December 4, 2023 Category: Drugs & Pharmacology Authors: Hendrik WesselsOliver von RichterMaria VelinovaJosef H öflerPaul ChamberlainArno KrommingaDirk LehnickKarsten Rotha Polpharma Biologics S.A, Gdansk, Polandb Hexal AG (A Sandoz company), Holzkirchen, Germanyc Early Development Services, ICON, Groningen, T Source Type: research
EE505 Cost-Effectiveness of Ofatumumab in Treatment of Relapsing Multiple Sclerosis in Turkey
The objective of this study is to evaluate the cost-effectiveness of ofatumumab against ocrelizumab and natalizumab for the treatment of Relapsing MS (RMS). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Tatar, B. Yarc ı, A.C. Akdemir, Ç Ölmez, F. İğde, E. Tınaz, M. Turanlı Source Type: research
EE353 Incorporation of Cladribine for Patients With Multiple Sclerosis in a Health Insurance Company in Brazil: Cost-Effectiveness
To assess the cost-effectiveness ratio of Cladribine compared to Natalizumab and Ocrelizumab for patients aged 18 years or older with Highly Active Multiple Sclerosis (HAMS). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J.M. Alves Junior, F.E. Prota, J.C.B. Martinelli, A. Chrispim, M. Serpeloni, I. Barreto, F.F. Christoforo, B.M. Nascimento, M. Ferreira Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
